Advanced in Migraine with Brainstem Aura

Dr. Melita L. Tate

Pediatrics | Internal Medicine
6160 S Yale Ave, 
Tulsa, OK 
Advanced in Migraine with Brainstem Aura
6160 S Yale Ave, 
Tulsa, OK 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Melita Tate is a primary care provider, practicing in Pediatrics and Internal Medicine in Tulsa, Oklahoma. Dr. Tate is rated as an Advanced provider by MediFind in the treatment of Migraine with Brainstem Aura. Her top areas of expertise are Familial Hemiplegic Migraine, Migraine with Brainstem Aura, Genital Warts, and Migraine.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 3 clinical trials in the study of Migraine with Brainstem Aura.

Specialties
Pediatrics
Internal Medicine
Licenses
Internal Medicine in OK
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
GlobalHealth
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

6160 S Yale Ave, Tulsa, OK 74136

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts
A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts
Enrollment Status: Completed
Publish Date: November 27, 2024
Intervention Type: Combination product
Study Phase: Phase 2
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee
Enrollment Status: Completed
Publish Date: March 28, 2024
Intervention Type: Drug
Study Drug: X0002
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
PROSPER-FM: Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management
PROSPER-FM: Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management
Enrollment Status: Completed
Publish Date: June 15, 2023
Intervention Type: Device, Other
Study Phase: Phase 3
View 6 Less Clinical Trials

1 Total Publications

Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts.
Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts.
Journal: American journal of clinical dermatology
Published: August 26, 2021
Similar Doctors
Experienced in Migraine with Brainstem Aura
Dr. George S. Miller
Pediatric Neurology | Pediatrics | Neurology
Experienced in Migraine with Brainstem Aura
Dr. George S. Miller
Pediatric Neurology | Pediatrics | Neurology

Cherokee Nation

100 S Bliss Ave, 
Tahlequah, OK 
 (55.4 miles away)
918-458-3100
Languages Spoken:
English
See accepted insurances

George Miller is a Pediatric Neurologist and a Pediatrics provider in Tahlequah, Oklahoma. Dr. Miller is rated as an Advanced provider by MediFind in the treatment of Migraine with Brainstem Aura. His top areas of expertise are Generalized Tonic-Clonic Seizure, Seizures, Myoclonic Epilepsy, and West Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tate's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile